We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
News

Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%

Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
News

Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"We are pursuing a very clear strategic path and wish to expand our expertise in the Life Science division further. The acquisition of the remaining approximately 50% of the shares in AJ Roboscreen allows us to meet the requirement of combining our expertise in molecular diagnostics and protein analytics with the expertise in the Group," said Klaus Berka, CEO of Analytik Jena AG.

In the future, in the Life Science growth segment, Analytik Jena wants to direct its focus more on the business with reagents, whereby the closer integration of the Leipzig-based subsidiary AJ Roboscreen GmbH is to play a central role. AJ Roboscreen GmbH develops diagnostic kits, reagents, fine chemicals and disposable consumables for the standardized purification and detection of nucleic acids as well as for detecting specific proteins. Admittedly, the diagnostics of neurodegenerative diseases, such as Parkinson’s or Alzheimer’s, still encompass a comparatively small market. However, in the long term, they harbor enormous potential.

Advertisement